Obinutuzumab: A review of its use in patients with chronic lymphocytic leukaemia

Drugs

Volumn 75, Issue 3, 2015, Pages 285-296

  Hoy, Sheridan M ^a  

^a NONE   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; OBINUTUZUMAB; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN HEMORRHAGE; CHRONIC LYMPHATIC LEUKEMIA; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; HEART ARREST; HUMAN; INFUSION RELATED REACTION; MONOTHERAPY; MULTIPLE MYELOMA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; PROGRESSION FREE SURVIVAL; RESPIRATORY FAILURE; RESPIRATORY TRACT INFECTION; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME; ANIMAL; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PATHOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;

EID: 84925499009     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-014-0340-3     Document Type: Article

References (31)

1. ®): non-Hodgkin's lymphoma (version 5.2014). 2014. http://www.nccn.org/. Accessed 24 Nov 2014.
2. Eichhorst B, Dreyling M, Robak T, et al. Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(Suppl 6):vi50-4.
3. Klein C, Lammens A, Schäfer W, et al. Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. mAbs. 2013;5(1):22-33.
4. Tam CS, Otero-Palacios J, Abruzzo LV, et al. Chronic lymphocytic leukaemia CD20 expression is dependent on the genetic subtype: a study of quantitative flow cytometry and fluorescent in-situ hybridization in 510 patients. Br J Haematol. 2008;141(1):36-40.
5. European Medicines Agency. Gazyvaro 1,000 mg concentrate for solution for infusion: summary of product characteristics. 2014. http://www.ema.europa.eu/ema/. Accessed 24 Nov 2014.
6. Genentech Inc. GAZYVA™ (obinutuzumab) injection, for intravenous infusion: prescribing information. 2014. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed 24 Nov 2014.
7. Herter S, Herting F, Mundigl O, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013;12(10):2031-42.
8. Rafiq S, Butchar JP, Cheney C, et al. Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. J Immunol. 2013;190(6):2702-11.
9. Herter S, Birk MC, Klein C, et al. Glycoengineering of therapeutic antibodies enhances monocyte/macrophage-mediated phagocytosis and cytotoxicity. J Immunol. 2014;192(5):2252-60.
10. Mössner E, Brünker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood. 2010;115(22):4393-402.
11. Flynn JM, Byrd JC, Kipps TJ, et al. Obinutuzumab (GA101) 1,000 versus 2,000 mg in patients with chronic lymphocytic leukemia (CLL): results of the phase II GAGE (GAO4768g) trial [abstract no. 7083]. J Clin Oncol. 2014;32(15 Suppl. 1).
12. Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101-10.
13. Salles G, Morschhauser F, Lamy T, et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood. 2012;119(22):5126-32.
14. Morschhauser F, Cartron G, Lamy T, et al. Phase I study of RO5072759 (GA101) in relapsed/refractory chronic lymphocytic leukemia [abstract no. 884]. Blood. 2009;114.
15. Cartron G, de Guibert S, Dilhuydy M-S, et al. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood. 2014;124(14):2196-202.
16. Sehn LH, Assouline SE, Stewart DA, et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood. 2012;119(22):5118-25.
17. Gibiansky E, Gibiansky L, Carlile DJ, et al. Population pharmacokinetics of obinutuzumab (GA101) in chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma and exposure-response in CLL. CPT Pharmacomet Syst Pharmacol. 2014;3:e144.
18. European Medicines Agency. Gazyvaro: CHMP assessment report. 2014. http://www.ema.europa.eu/ema/. Accessed 24 Nov 2014.
19. US FDA Center for Drug Evaluation and Research. Medical review: GAZYA (obinutuzumab). 2013. http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed 24 Nov 2014.
20. Freeman CL, Dixon M, Houghton R, et al. Risk factors associated with the development of infusion-related reactions in patients with chronic lymphocytic leukaemia treated with anti-CD20 monoclonal antibodies: analysis of the CLL11 study dataset [abstract no. 3339]. In: 56th American Society of Hematology Annual Meeting and Exposition; 2014.
21. Morschhauser A, Salles G, Cartron G, et al. Dose selection for phase III studies of the monoclonal anti-CD20 antibody obinutuzumab (GA101): a rational approach [abstract no. 0935]. Haematologica. 2011;96(Suppl 2):390.
22. Chang C-H, Rossi EA, Goldenberg DM. Monoclonal antibodies targeting CD20. mAbs. 2013;5(3):335-6.
23. O'Brien S, Wierda WG, Faderl S, et al. FCR-3 as frontline therapy for patients with chronic lymphocytic leukemia [abstract no. 2117]. Blood. 2005;106.
24. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001;19(8):2165-70.
25. Cameron H, Thompson M, Marino J-P, et al. Obinutuzumab and chlorambucil versus chlorambucil monotherapy for treatment of previously untreated chronic lymphocytic leukemia where fludarabine-based chemotherapy is considered inappropriate: a Canadian cost-utility analysis [abstract no. 1288]. In: 56th American Society of Hematology Annual Meeting and Exposition; 2014.
26. Walzer S, Becker U, Samanta K, et al. The potential cost-effectiveness of obinutuzumab (GA101) in combination with chlorambucil in chronic lymphocytic leukemia [abstract no. PCN112]. Value Health. 2013;16(7):A412.
27. Veenstra DL, Reyes CM, Ramsey SD. Is obinutuzumab cost-effective in the first-line treatment of CLL? [abstract no. 7052]. J Clin Oncol. 2014;32(15 Suppl. 1).
28. Reyes C, Gazauskas G, Becker U, et al. Cost-effectiveness analysis of obinutuzumab versus ofatumumab for previously untreated chronic lymphocytic leukemia (CLL) [abstract no. 1324]. In: 56th American Society of Hematology Annual Meeting and Exposition; 2014.
29. National Institute for Health and Care Excellence. NICE set to recommend another leukaemia drug. 2014. https://www.nice.org.uk/. Accessed 3 Dec 2014.
30. National Health Service. National Cancer Drug Fund prioritization scores: obinutuzumab. 2014. http://www.england.nhs.uk/. Accessed 19 Nov 2014.
31. Waterboer T, Moreno SG, Shang A, et al. Indirect treatment comparisons of obinutuzumab (GA101) plus chlorambucil (Clb) versus bendamustine and versus ofatumumab plus Clb in patients with chronic lymphocytic Leukemia [abstract no. PSY9]. Value Health. 2014;17(3):A225.